Evidence map›Paper›PMID 39233831›Full record

ArticleNeuro-oncology advances

Glioma oncogenesis in the Constitutional mismatch repair deficiency (CMMRD) syndrome.

Lea Guerrini-Rousseau, Jane Merlevede, Philippe Denizeau, Felipe Andreiuolo, Pascale Varlet, Stéphanie Puget, Kevin Beccaria, Thomas Blauwblomme, Odile Cabaret, Nadim Hamzaoui and 10 more

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lea Guerrini-RousseauDepartment of Children and Adolescents Oncology, Gustave Roussy, Villejuif, France.ORCID https://orcid.org/0000-0003-0050-5407
Jane MerlevedeMolecular Predictors and New Targets in Oncology, INSERM U981, Team "Genomics and Oncogenesis of pediatric Brain Tumors," Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Philippe DenizeauClinical Genetics, Rennes University Hospital, Rennes, France.
Felipe AndreiuoloNeuropathology and INSERM UMR1266 IMA-Brain, GHU-Paris Psychiatry and Neuroscience, Sainte-Anne Hospital, Paris, France.
Pascale VarletNeuropathology and INSERM UMR1266 IMA-Brain, GHU-Paris Psychiatry and Neuroscience, Sainte-Anne Hospital, Paris, France.
Stéphanie PugetNeurosurgery, Necker Hospital, Paris University, Paris, France.
Kevin BeccariaNeurosurgery, Necker Hospital, Paris University, Paris, France.
Thomas BlauwblommeNeurosurgery, Necker Hospital, Paris University, Paris, France.ORCID https://orcid.org/0000-0003-4076-9642
Odile CabaretDepartment of Medical Genetics, Gustave Roussy, Villejuif, France.ORCID https://orcid.org/0000-0003-2646-6952
Nadim HamzaouiService de Génétique et Biologie Moléculaires, Hôpital Cochin, APHP Centre Université de Paris, Paris, France.
Franck BourdeautTranslational Research in Pediatric Oncology (RTOP), INSERM U830 Laboratory of Genetics and Biology of Cancers, SIREDO: Care, Innovation, and Research for Children, Adolescents and Young Adults with Cancer, Curie Institute, Paris University, Paris, France.ORCID https://orcid.org/0000-0001-9489-6781
Cécile Faure-ConterPediatric Hematology and Oncology Institute (IHOPE), Centre Leon Berard, Lyon, France.
Martine MulerisCentre de Recherche Saint-Antoine, Sorbonne Université, Paris, France.
Chrystelle ColasDépartement de Génétique, Institut Curie, Université Paris Sciences Lettres, Paris, France.
Tiphaine Adam de BeaumaisDepartment of Children and Adolescents Oncology, Gustave Roussy, Villejuif, France.
David CastelMolecular Predictors and New Targets in Oncology, INSERM U981, Team "Genomics and Oncogenesis of pediatric Brain Tumors," Gustave Roussy, Université Paris-Saclay, Villejuif, France.ORCID https://orcid.org/0000-0003-0247-080X
Etienne RouleauDepartment of Medical Genetics, Gustave Roussy, Villejuif, France.ORCID https://orcid.org/0000-0002-9046-257X
Laurence BrugièresDepartment of Children and Adolescents Oncology, Gustave Roussy, Villejuif, France.ORCID https://orcid.org/0000-0002-7798-6651
Jacques GrillDepartment of Children and Adolescents Oncology, Gustave Roussy, Villejuif, France.ORCID https://orcid.org/0000-0003-4773-3001
Marie-Anne DebilyMolecular Predictors and New Targets in Oncology, INSERM U981, Team "Genomics and Oncogenesis of pediatric Brain Tumors," Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Constitutional mismatch repair deficiency (CMMRD) is a cancer predisposition due to biallelic mutations in one of the mismatch repair (MMR) genes associated with early onset of cancers, especially high-grade gliomas. Our aim was to decipher the molecular specificities of these gliomas. Methods: Clinical, histopathological, and whole exome sequencing data were analyzed in 12 children with genetically proven CMMRD and a high-grade glioma. Results: PDL1 expression was present in immunohistochemistry in 50% of the samples. In 9 patients, the glioma harbored an ultra-hypermutated phenotype (104-635 coding single nucleotide variants (SNV) per Mb, median 204). Driver mutations in Conclusions: CMMRD-associated gliomas have a specific oncogenesis that does not involve usual pathways and mutations seen in sporadic pediatric or adult glioblastomas. Frequent alterations in other pathways such as MAPK may suggest the use of other targeted therapies along with PD1 inhibitors.

Indexed as

cancer predispositionCMMRDconstitutional mismatch repair deficiencyglioblastomamutational signaturesmutation burden

Identifiers

PMID39233831
PMCPMC11372297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.